Approval of composition of matter patent in key jurisdiction underscores the Company's commitment to maximize future out-licensing value
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company's lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders. This approval follows the recent patent grant in Australia, highlighting Conduit's continued progress in safeguarding its intellectual property portfolio for future out-licensing opportunities.
"This approval represents another significant milestone in our efforts to maximize the value of our intellectual property portfolio," said Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals. "The granting of this patent in Japan, one of the world's largest pharmaceutical markets, underscores the strength of our scientific and intellectual property strategy. We look forward to securing additional approvals in other major markets, further enhancing our global patent coverage and bolstering our out-licensing opportunities."
About Conduit Pharmaceuticals
Conduit Pharmaceuticals (Nasdaq: CDT) has developed a unique business model to bring medicines to patients. Its novel approach addresses unmet medical needs by enhancing and extending the intellectual property of its existing assets through cutting-edge solid-form technology, then commercializing these products with life science companies.
Conduit holds an exclusive license with AstraZeneca for the rights to AZD1656 and AZD5658, both Glucokinase Activators, and AZD5904, a myeloperoxidase inhibitor. Additionally, the Company has two further cocrystal assets including CDT1656, a combination of AZD1656 and a known compound, further broadening its innovative portfolio. Conduit is targeting Lupus and ANCA Vasculitis as its lead indications.
Conduit is led by a highly experienced team of pharmaceutical executives, including CEO, Dr. David Tapolczay, former Chief Executive Officer of UK-based medical research charity LifeArc, and the Chair of our Board, Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer, Inc.
在关键法域批准物质组成专利凸显了公司最大化未来外部授权价值的承诺
美国佛罗里达州那不勒斯和英国剑桥，2024年11月21日（全球新闻稿）-- Conduit Pharmaceuticals Inc.（纳斯达克股票代码：CDT）（"Conduit Pharmaceuticals"或"Conduit"或"公司"）今天宣布，日本专利局（JPO）已批准该公司主要资产AZD1656的物质组成专利申请，该药物是一种针对广泛自身免疫疾病的糖激酶激活剂。这一批准是在澳洲最近获得专利的基础上，突显了Conduit在保护其知识产权组合方面的持续进展，以便未来的许可机会。
"这一批准代表了我们最大化知识产权组合价值努力的另一个重要里程碑，" Conduit Pharmaceuticals首席执行官大卫·塔波尔茨曾说。"在全球最大的药品市场之一日本授予这一专利，凸显了我们科学和知识产权策略的强大。我们期待在其他主要市场中获得更多批准，进一步增强我们的全球专利覆盖面，并增强我们的外部授权机会。"
关于Conduit Pharmaceuticals
Conduit制药集团（纳斯达克：CDT）开发了一种独特的业务模式，以将药物带给患者。其新颖的方法通过尖端的固态技术增强和延伸其现有资产的知识产权，解决未满足的医疗需求，然后与生命科学公司共同商业化这些产品。
Conduit与阿斯利康签订了AZD1656和AZD5658的独家许可，二者均为葡萄糖激酶激动剂，以及AZD5904，一种髓过氧化物酶抑制剂。此外，公司还有两个进一步的共晶资产，包括CDT1656，这是AZD1656和一种已知compound的组合，进一步拓宽了其创新组合。Conduit的主要目标是狼疮和ANCA血管炎。
Conduit由一支经验丰富的药品高管团队领导，包括首席执行官大卫·塔波茨（Dr. David Tapolczay），他曾是英国医疗研究慈善组织LifeArc的首席执行官，以及我们的董事会主席弗雷达·刘易斯-霍尔（Dr. Freda Lewis-Hall），她曾是辉瑞公司的首席医疗官。
